Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL30163273

N#Cc1cc(-c2ccc3c(c2CC(=O)O)CCC3)ccn1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 5/20 0.55
MYC P01106 1/20 0.36
XDH P47989 1/20 0.35
SLC22A12 Q96S37 1/20 0.35
LNPEP Q9UIQ6 2/20 0.33
CGAS Q8N884 1/20 0.33
EED O75530 1/20 0.33
RBBP4 Q09028 1/20 0.33
SUZ12 Q15022 1/20 0.33
EZH2 Q15910 1/20 0.33
AEBP2 Q6ZN18 1/20 0.33
RXRB P28702 4/20 0.32
RXRA P19793 3/20 0.32
RXRG P48443 3/20 0.32
PRKCE Q02156 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
NPY5R Q15761 1/20 0.32
PPARA Q07869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22802360 0.94 NLRP3 (0.59) NLRP3MYCXDHSLC22A12LNPEP
SCHEMBL22802375 0.85 NLRP3 (0.59) NLRP3MYCXDHSLC22A12LNPEP
Trifluoroacetic Acid SCHEMBL30163374 0.84 NLRP3 (0.41) NLRP3LNPEPRXRBRXRARXRG
Trifluoroacetic Acid SCHEMBL30163366 0.82 NLRP3 (0.54) NLRP3SLC22A12LNPEPRXRBRXRA
SCHEMBL30163238 0.82 NLRP3 (0.54) NLRP3MYCXDHSLC22A12LNPEP
SCHEMBL22802381 0.82 NLRP3 (0.54) NLRP3MYCXDHSLC22A12LNPEP
SCHEMBL22802363 0.77 NLRP3 (0.44) NLRP3LNPEPRXRBRXRARXRG
SCHEMBL22802368 0.75 NLRP3 (0.59) NLRP3RXRBRXRARXRG
SCHEMBL24922421 0.73 NLRP3 (0.48) NLRP3MYCXDHSLC22A12EED
SCHEMBL20634909 0.73 NLRP3 (0.45) NLRP3MYCXDHSLC22A12EED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030879-B2 Sulfonyl acetamides as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2024-07-09 US disclosed
US-11884645-B2 Sulfonyl acetamides as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2024-01-30 US disclosed
US-11834433-B2 Compounds INFLAZOME LIMITED (IE) 2023-12-05 US disclosed
US-11530200-B2 Compounds INFLAZOME LIMITED (IE) 2022-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030879-B2 Sulfonyl acetamides as NLRP3 inhibitors NLRP3, NOD1, NLRP1 NLRP3 1/4885MYC 4225/4885XDH 100/4885
US-11884645-B2 Sulfonyl acetamides as NLRP3 inhibitors NLRP3, NOD1, ABCC5 NLRP3 1/4885MYC 4177/4885XDH 105/4885
US-11834433-B2 Compounds NLRP3, NOD1, PYCARD NLRP3 1/4885MYC 2519/4885XDH 16/4885
US-11530200-B2 Compounds NLRP3, NOD1, NLRP1 NLRP3 1/4885MYC 2959/4885XDH 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.